Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Low dose naltrexone (LDN) has become a cornerstone tool in integrative and functional medicine for autoimmune disease, chronic pain, fibromyalgia, mast cell activation syndrome (MCAS), and a growing list of neuroinflammatory conditions. Most clinicians who prescribe LDN are familiar with its opioid receptor mechanism — transient mu-opioid blockade triggering a compensatory upregulation of endogenous opioids (beta-endorphin and met-enkephalin), including the opioid growth factor (OGF)–OGF receptor axis. Fewer clients, and honestly fewer prescribers, are equally familiar with LDN's second mechanism: direct antagonism of Toll-like receptor 4 (TLR4) on microglia and macrophages. This second pathway is where the opportunity for rational potentiation lives.

Why TLR4 Matters for LDN's Anti-Inflammatory Effect

TLR4 is the receptor responsible for detecting lipopolysaccharide (LPS) from gram-negative bacteria, as well as endogenous damage-associated molecular patterns (DAMPs) released after tissue injury or cellular stress. When LPS or a DAMP binds the TLR4/MD-2 co-receptor complex, the complex dimerizes and recruits the MyD88 and TRIF adaptor pathways, driving NF-κB activation and a cascade of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) plus nitric oxide and reactive oxygen species. In the central nervous system, this same pathway is the primary driver of microglial activation — the process underlying much of the "brain fog," central sensitization, and neuroinflammatory symptom burden seen in fibromyalgia, Long COVID, and complex regional pain syndrome (CRPS).

The discovery that naltrexone and naloxone antagonize TLR4 — independent of their opioid receptor activity — reframed LDN from a purely endorphin-based therapy into a genuine glial modulator. The opioid-inactive (+)-isomer of naltrexone, which has no meaningful classical opioid receptor affinity, still acts as a TLR4 antagonist: in the foundational work from Linda Watkins' group, (+)-naltrexone suppressed TLR4-driven microglial activation and reversed neuropathic pain in animal models. Clinically, this dual mechanism is one reason LDN's benefit profile extends well beyond what endorphin modulation alone would predict — and it is also why LDN's real-world potency is modest and variable: naltrexone is a comparatively low-affinity TLR4 antagonist. Newer synthetic naltrexone derivatives engineered purely for TLR4 potency have shown roughly several thousand-fold greater TLR4 antagonism than the parent compound — one recent (+)-naltrexone derivative, CIAC101, reported approximately 6,200-fold higher potency. While not clinically available, this is a useful proof of concept: the TLR4 axis has substantially more room to be pushed than LDN alone provides.

This creates a rational, mechanistically coherent argument for pairing LDN with adjunctive agents that engage the same TLR4/MD-2 axis through complementary binding modes, rather than simply increasing the LDN dose — which does not reliably improve outcomes and, at higher doses, can antagonize the opioid-receptor-dependent arm of LDN's mechanism.

Adjunctive Agents With the Best-Characterized TLR4/MD-2 Activity

Not all "anti-inflammatory" botanicals act at TLR4. The agents below have direct, mechanistically documented interaction with the TLR4/MD-2 complex — either by occupying the LPS-binding hydrophobic pocket of MD-2, forming a covalent adduct at a reactive cysteine residue, or physically disrupting TLR4/MD-2 dimerization.

Xanthohumol (hops, Humulus lupulus)

Xanthohumol, the principal prenylated chalcone in hops, embeds into the hydrophobic pocket of MD-2, forming stable hydrogen bonds with the Arg-90 and Tyr-102 residues — the same region LPS itself must occupy — giving it a genuinely competitive antagonist profile at the co-receptor level. Human studies using oral xanthohumol at doses achievable through concentrated hop extract have shown measurable suppression of pro-inflammatory cytokine output from peripheral blood mononuclear cells following an inflammatory challenge, suggesting the mechanism translates beyond the test tube even at modest, food-derived doses.

Sulforaphane and iberin (cruciferous vegetables)

Sulforaphane — and its structural cousin iberin, both isothiocyanates concentrated in broccoli sprout extracts — works through a distinct, thiol-dependent mechanism: it forms covalent adducts with specific cysteine residues on both TLR4 itself (extracellular cysteines including Cys246 and Cys609) and on MD-2 (notably Cys133), sterically blocking the LPS–MD-2 interaction and preventing TLR4 oligomerization. Because this effect is thiol-dependent, it was reversed in the original binding studies by co-incubation with N-acetylcysteine (NAC) or dithiothreitol — a detail worth knowing clinically, since a client simultaneously taking high-dose NAC may partially blunt sulforaphane's TLR4 effect.

Curcumin (turmeric, Curcuma longa)

Curcumin binds MD-2 directly at submicromolar affinity, occupying the same hydrophobic LPS pocket without forming a covalent bond (unlike sulforaphane), and reduces TLR4/NF-κB signaling across multiple inflammatory models. Its clinical limitation is not mechanism but pharmacokinetics — curcumin's poor aqueous solubility and rapid first-pass metabolism mean that unformulated curcumin achieves only a fraction of the exposure implied by in vitro potency data. This is precisely why bioavailability-enhanced preparations (phospholipid-complexed, nanoparticle, or piperine–co-administered formulations) matter clinically far more for this compound than for most other botanicals discussed here.

Celastrol (thunder god vine, Tripterygium wilfordii)

Celastrol, the principal bioactive triterpenoid from thunder god vine, is a thiol-reactive Michael acceptor that covalently modifies cysteine residues and blocks LPS binding to the TLR4/MD-2 complex in a thiol-dependent manner. It is mechanistically potent — arguably among the most potent natural TLR4/MD-2 antagonists on this list — but that same electrophilic reactivity underlies its known dose-dependent hepatotoxicity and gastrointestinal toxicity signals seen with Tripterygium extract use. Celastrol is not an agent for casual or unsupervised adjunctive use; if considered at all, it belongs in a monitored, standardized-extract, time-limited protocol.

Sparstolonin B (Sparganium stoloniferum / Scirpus yagara)

Sparstolonin B, a xanthone-isocoumarin compound derived from rhizomes used in traditional Chinese medicine, has been characterized in preclinical models as a selective TLR2/TLR4 antagonist that blocks early intracellular signaling and reduces LPS-induced cytokine production. It remains almost entirely a research-grade compound without established human dosing or commercial extract standardization — worth tracking as an emerging option rather than recommending today.

A Practical Framework, Not a Fixed Protocol

The strongest, lowest-risk starting point for most clients on LDN is dietary and supplement-level TLR4 support that has both mechanistic and human safety data: broccoli sprout extract (sulforaphane), a standardized hop-derived xanthohumol extract, and a bioavailability-enhanced curcumin formulation. These three act at overlapping but non-identical sites on the TLR4/MD-2 complex, so there is a reasonable rationale — though not head-to-head clinical trial data — for modest synergy rather than redundancy when used together at conservative doses. Celastrol-containing extracts warrant a materially higher bar: they are reserved for clients with an established inflammatory burden not responding to first-line adjuncts, ideally with baseline and follow-up hepatic function monitoring, given the toxicity profile.

It is worth being explicit about what the evidence does and does not support. Almost all of the TLR4-level mechanistic data above comes from in vitro binding assays, molecular docking, and rodent inflammation models. Direct clinical trial evidence combining any of these agents with LDN specifically does not yet exist. What exists is a coherent, receptor-level rationale: LDN is a genuine but modest-affinity TLR4/MD-2 antagonist; these botanicals are also genuine — in some cases higher-affinity — TLR4/MD-2 antagonists acting through different binding modes on the same complex; and combining mechanistically complementary, low-toxicity agents is a standard functional medicine strategy for building a therapeutic effect that a single agent's affinity or bioavailability limitations cannot achieve alone. This is hypothesis-informed integrative practice, not an established combination protocol, and it should be individualized, sequenced, and monitored the way any other complex regimen would be — with attention to a client's inflammatory phenotype, concurrent medications, hepatic status, and response over time.

If you are a current client and would like to discuss whether a TLR4-focused adjunctive strategy makes sense for your situation, this is exactly the kind of individualized decision best made together in the context of your full history.

References

1. Hutchinson MR, Zhang Y, Brown K, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci. 2008;28(1):20-29. PMID 18662331. https://pmc.ncbi.nlm.nih.gov/articles/PMC2588470/
2. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-459. PMC3962576. https://pmc.ncbi.nlm.nih.gov/articles/PMC3962576/
3. Real-world effectiveness and tolerability of low dose naltrexone to treat chronic pain: a retrospective cohort study of one pain physician's practice. PMC12702260. https://pmc.ncbi.nlm.nih.gov/articles/PMC12702260/
4. Immunometabolic modulatory role of naltrexone in BV-2 microglia cells. Int J Mol Sci. PMC8395119. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395119/
5. Gao J, Lin C, Deng L, Wang H, Wang X. Nanomolar TLR4 antagonist CIAC101 derived from (+)-naltrexone blocks microglial activation and methamphetamine addiction. J Med Chem. 2025;68(23):25469-25484. https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c02596
6. Determination of the binding mode for anti-inflammatory natural product xanthohumol with myeloid differentiation protein 2. Drug Des Devel Ther. 2016;10:455-463. PMID 26869767. https://pubmed.ncbi.nlm.nih.gov/26869767/
7. Jung F, Staltner R, Tahir A, et al. Oral intake of xanthohumol attenuates lipoteichoic acid-induced inflammatory response in human PBMCs. Eur J Nutr. 2022;61(8):4155-4166. PMC9596557. https://pmc.ncbi.nlm.nih.gov/articles/PMC9596557/
8. Koo JE, Park ZY, Kim ND, Lee JY. Sulforaphane inhibits the engagement of LPS with TLR4/MD2 complex by preferential binding to Cys133 in MD2. Biochem Biophys Res Commun. 2013;434(3):600-605. PMID 23583403. https://pubmed.ncbi.nlm.nih.gov/23583403/
9. Youn HS, Kim YS, Park ZY, et al. Sulforaphane suppresses oligomerization of TLR4 in a thiol-dependent manner. J Immunol. 2010;184(1):411-419. PMID 19949083. https://journals.aai.org/jimmunol/article/184/1/411/81870/
10. Gradišar H, Keber MM, Pristovšek P, Jerala R. MD-2 as the target of curcumin in the inhibition of response to LPS. J Leukoc Biol. 2007;82(4):968-974. PMID 17609337. https://pubmed.ncbi.nlm.nih.gov/17609337/
11. Wang Y, Shan X, Chen G, et al. New MD2 inhibitors derived from curcumin with improved anti-inflammatory activity. Eur J Med Chem. 2018;148:291-305. PMID 29466778. https://pubmed.ncbi.nlm.nih.gov/29466778/
12. Lee JY, Lee BH, Kim ND, Lee JY. Celastrol blocks binding of lipopolysaccharides to a Toll-like receptor4/myeloid differentiation factor2 complex in a thiol-dependent manner. J Ethnopharmacol. 2015;172:254-260. PMID 26116162. https://pubmed.ncbi.nlm.nih.gov/26116162/
13. Cascão R, Fonseca JE, Moita LF. Celastrol: a spectrum of treatment opportunities in chronic diseases. Front Med (Lausanne). 2017;4:69. PMC5471334. https://pmc.ncbi.nlm.nih.gov/articles/PMC5471334/
14. Zhang X, Wang Y, Ge HY, et al. Celastrol reverses palmitic acid (PA)-caused TLR4-MD2 activation-dependent insulin resistance via disrupting MD2-related cellular binding to PA. J Cell Physiol. 2018;233(10):6814-6824. PMID 29667734. https://pubmed.ncbi.nlm.nih.gov/29667734/
15. Liang Q, Wu Q, Jiang J, et al. Characterization of sparstolonin B, a Chinese herb-derived compound, as a selective Toll-like receptor antagonist with potent anti-inflammatory properties. J Biol Chem. 2011;286(30):26470-26479. PMC3143611. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143611/

About Dr. Kim

Yoon Hang Kim, MD, MPH is Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician, with more than 20 years of experience in integrative and functional medicine. He completed a fellowship in Integrative Medicine at the University of Arizona under Dr. Andrew Weil, holds UCLA certification in medical acupuncture, and is board-certified in both Preventive Medicine and Integrative & Holistic Medicine. Dr. Kim specializes in low dose naltrexone (LDN) therapy, autoimmune disease, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome (CFS), mast cell activation syndrome (MCAS), and mold/biotoxin illness. He is the author of three books and more than 20 published articles.

Learn more at www.yoonhangkim.com | www.directintegrativecare.com

Membership and fee information: Direct Care Fee Schedule